Bharesh Chauhan, DPhil (Oxon), Joins Pittsburgh-Based Contract Research Organization, Clinical Research Strategies, LLC as Clinical and Regulatory Affairs Scientist
Pittsburgh, PA – January 13, 2022. Clinical Research Strategies, LLC (“CRS”), a Pittsburgh-area-based, US-owned and operated contract research organization (CRO) and executive management consultancy for the life sciences industry is pleased to announce the addition of Bharesh Chauhan, D.Phil. (Oxon) to the firm as a Clinical and Regulatory Affairs Scientist. Dr. Chauhan earned his doctorate from Oxford University in Molecular Virology, where he conducted early studies in the generation of the now established baculovirus expression system employed for viral vaccines and gene therapy vectors. He came to the U.S. where he has spent the last 22 years on ocular and rare disease research yielding more than 20 peer-reviewed papers, numerous national and international presentations at research conferences, and acting as a reviewer of scientific manuscripts and grants.
At the Albert Einstein College of Medicine in New York, his research focused on cataracts, conducting both gene regulation and high-throughput gene expression analyses. While at the nationally leading Cincinnati Children’s Research Foundation, he focused on development of eye tissues important in understanding congenital ocular diseases, where he primarily utilized transgenic mouse models of eye disease with state of the art imaging devices to probe the molecular and cellular biology of anterior ocular diseases. Dr. Chauhan worked at the UPMC Children’s Hospital of Pittsburgh to translate his basic research to the bedside by primarily performing studies on human tissues.
CRS CEO and Chief Quality and Regulatory Officer, David Link, MBA, remarks, “We are excited about the addition of an expert at the level of Dr. Chauhan who joins us for our ophthalmologic and rare disease clients.” Alethea Wieland, President and Co-founder adds, “Bharesh adds an impressive set of skills and value to our firm and we are lucky that his rare disease expertise enables the precision medicine work that our business partners and clients face in the new frontier of medicine and research.”
About Clinical Research Strategies, LLC:
CRS is a specialty CRO and executive management consulting firm that fits-for-purpose veteran life sciences executives, attorneys, regulatory scientists and strategists, clinical operations, project management, quality assurance engineers, and sales and marketing teams to take on the biggest challenges for start-up, mid-sized, and large life sciences companies, many of whom are developing novel, first-in-class drugs, biologics, diagnostics and medical devices, or software as a medical device (SaMD). Service areas are clinical trials, Functional Service Provider (FSP) models, selection and management of CROs, regulatory compliance strategy and submissions, QMS, EU MDR and GDPR, rescue trials, TMF, risk mitigation and remediation, training high-performing teams, staffing solutions, and decentralized trials.
Indications represented are precision medicine, immuno-oncology, central nervous system, infectious diseases, respiratory diseases, orthopedics, de novo devices, digital health and mobile apps, reproductive health, regenerative medicine, cardiology, major depressive disorder, opioid-sparing pain, cannabis, radiology, and critical care. CRS is a qualified service provider for federal grants.
CRS is an inclusive employer and does not discriminate in employment on the basis of race, color, religion, sex, gender identity, national origin, political affiliation, sexual orientation, marital status, disability, genetic information, age, education, membership in an employee organization, parental status, military service, or other non-merit factor. CRS does not tolerate censorship, surveillance, bullying, intimidation, retaliation, discrimination, or harassment of any kind.
# # #
Step2 Branding & Design
Alethea Wieland, President and Founder
Clinical Research Strategies, LLC